Obesity And Diabetes TII Treatment EndoBarrier® Enters U.S. Pivotal Clinical Trial

GI Dynamics, Inc. (ASX: GID) have announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier®, the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.

Read more

Posted in Type II Drugs